Search

everythinglearnresearchcommunity

for

Search:↓

Both treatments are similarly effective, but paclitaxel-carboplatin is cheaper and has more severe side effects.

MK-5108 is safe and shows potential against tumors, especially alone.

Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.

Long-term treatment with palbociclib plus letrozole maintains quality of life in certain breast cancer patients.

Immunotherapy with pembrolizumab significantly reduced cancer in a young woman with adrenocortical carcinoma.

Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.

Sorafenib can cause a unique skin reaction.

Neoadjuvant chemotherapy followed by surgery leads to fewer severe complications and better quality of life than immediate surgery in advanced ovarian cancer patients with high tumor load.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Selumetinib significantly reduced tumor size and improved vision in a child with neurofibromatosis type 1.

Combining gemcitabine with paclitaxel is more effective than with pemetrexed for advanced lung cancer.

The treatment was effective for advanced non-Hodgkin's lymphomas.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

Sorafenib often causes mucositis, hand-foot syndrome, rash, alopecia, diarrhea, and fatigue.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

The drug combination was safe and showed promise in treating advanced tumors.

A young woman with kidney cancer experienced rare hair loss from a cancer drug and unusual cancer spread, suggesting early drug treatment might reduce spread and prolong survival.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

CAP7.1 is generally safe at 200 mg/m²/day, but can cause fatigue, nausea, hair loss, fever, and blood-related issues.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Pantethine may boost the immune system's ability to fight sarcoma.

Selumetinib effectively reduces tumor size in many children with neurofibromatosis type 1, but can cause skin and hair issues.

PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.

Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.

Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.

The nanocomposite effectively targets lung cancer cells without harming normal cells.

Ocoxin improves quality of life for advanced ovarian cancer patients on chemotherapy.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.